AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31072856 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychiatrists' experiences and perspectives on treating DS patients
Number of subjects: 10
Study 31072856 — intervention group
Group type: EXPERIMENTAL
Intervention: Other healthcare professionals' attitudes towards DS
Number of subjects: 10
Study 28296763 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg M-001
Number of subjects: 222
Study 28296763 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg M-001
Number of subjects: 222
Study 28296763 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 222
Study 28296763 — intervention group
Group type: EXPERIMENTAL
Intervention: M-001
Number of subjects: 222
Study 25715171 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone and clinical case management for 12 weeks
Number of subjects: 108
Study 25715171 — intervention group
Group type: COMPARATOR
Intervention: Citalopram
Number of subjects: 108
Study 25715171 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 24019052 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral educational intervention targeting modifiable factors associated with postpartum depressive symptoms
Number of subjects: 540
Study 24019052 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care (control)
Number of subjects: 540
Study 20935327 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-linguistic treatment (CLT), 6 months, at least 2 hours per week
Number of subjects: 80
Study 20935327 — intervention group
Group type: COMPARATOR
Intervention: Communicative treatment, 6 months, at least 2 hours per week
Number of subjects: 80
Study 20935327 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-linguistic treatment (CLT)
Number of subjects: 80
Study 19522781 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based ecologically based family therapy (EBFT)
Number of subjects: 119
Study 19522781 — intervention group
Group type: EXPERIMENTAL
Intervention: Office-based functional family therapy (FFT)
Number of subjects: 119
Study 19522781 — intervention group
Group type: COMPARATOR
Intervention: Service as usual (SAU)
Number of subjects: 119
Study 16960264 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anesthesia with deliberate hypotension (target mean arterial pressure of 55-60 mmHg)
Number of subjects: 102
Study 16960264 — intervention group
Group type: COMPARATOR
Intervention: Control group (general anesthesia without deliberate hypotension)
Number of subjects: 102
Study 16960264 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anesthesia with deliberate hypotension
Number of subjects: 102
Study 15055821 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 months treatment with growth hormone (2 IU/day)
Number of subjects: 19
Study 15055821 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 19
Study 11218239 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (mean, 0.12 mg/kg/day) plus oral glutamine (mean, 28 g/day) and parenteral glutamine (mean, 5.2 g/day) for 28 days
Number of subjects: 8
Study 11218239 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 8
Study 11218239 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone and glutamine treatment
Number of subjects: 8
Study 9355019 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment (AT) for 18 +/- 6 months
Number of subjects: 10
Study 9355019 — intervention group
Group type: COMPARATOR
Intervention: Low salt diet (LSD)
Number of subjects: 10
Study 9355019 — intervention group
Group type: COMPARATOR
Intervention: High salt diet (HSD)
Number of subjects: 10
Study 9355019 — intervention group
Group type: COMPARATOR
Intervention: Placebo for at least eight weeks
Number of subjects: 10
Study 9355019 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment (AT)
Number of subjects: 10
Study 8219435 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 21
Study 8219435 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 21
Study 8219435 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 3315478 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone sodium succinate (MPSS) 30 mg/kg
Number of subjects: 304
Study 3315478 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 304
Study 31462735 — intervention group
Group type: EXPERIMENTAL
Intervention: Obinutuzumab (G) plus bendamustine (Benda) induction followed by G maintenance
Number of subjects: 88
Study 31462735 — intervention group
Group type: COMPARATOR
Intervention: Bendamustine (Benda) induction alone
Number of subjects: 88
Study 31462735 — intervention group
Group type: EXPERIMENTAL
Intervention: MRD-negative patients at EOI
Number of subjects: 88
Study 29626045 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention video (more emotional impact)
Number of subjects: 8353
Study 29626045 — intervention group
Group type: COMPARATOR
Intervention: Control video (less emotional impact)
Number of subjects: 8353
Study 29626045 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention video
Number of subjects: 8353
Study 29626045 — intervention group
Group type: COMPARATOR
Intervention: Control video
Number of subjects: 8353
Study 28626765 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum metabolomics profiling using 1H NMR
Number of subjects: 101
Study 28626765 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 101
Study 25764403 — intervention group
Group type: EXPERIMENTAL
Intervention: Videolaryngoscope
Number of subjects: 100
Study 25764403 — intervention group
Group type: COMPARATOR
Intervention: Fibreoptic intubation
Number of subjects: 100
Study 25764403 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 100
Study 23030309 — intervention group
Group type: EXPERIMENTAL
Intervention: Test drug (candesartan cilexetil 16 mg)
Number of subjects: 40
Study 23030309 — intervention group
Group type: COMPARATOR
Intervention: Reference drug (candesartan cilexetil 16 mg)
Number of subjects: 40
Study 23030309 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations (test and reference)
Number of subjects: 40
Study 20605254 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 1212
Study 20605254 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1212
Study 18044014 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrogram-guided ablation (EGA)
Number of subjects: 30
Study 18044014 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion of isoproterenol (20 mug/min) during repeat ablation
Number of subjects: 30
Study 18044014 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat ablation targeting CFAEs and mapping all pulmonary veins (PVs)
Number of subjects: 30
Study 15019120 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine granules 0.5 g/kg orally for 14 days
Number of subjects: 48
Study 15019120 — intervention group
Group type: COMPARATOR
Intervention: Placebo (same dosage as glutamine) for 14 days
Number of subjects: 48
Study 11805533 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg)
Number of subjects: 1145
Study 9935254 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg trovafloxacin once daily for 10 days
Number of subjects: 19
Study 9935254 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 7755476 — intervention group
Group type: EXPERIMENTAL
Intervention: cilazapril 2.5-5 mg per day
Number of subjects: 17
Study 7755476 — intervention group
Group type: COMPARATOR
Intervention: atenolol 25-100 mg per day
Number of subjects: 17
Study 2971977 — intervention group
Group type: EXPERIMENTAL
Intervention: Metered dose aerosol of 200 micrograms fenoterol plus 80 micrograms ipratropium bromide ('Duovent')
Number of subjects: 20
Study 2971977 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry powder preparation for inhalation ('Inhalets') of 200 micrograms fenoterol plus 80 micrograms ipratropium bromide ('Duovent')
Number of subjects: 20
Study 31449165 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented PROMs (Patient-Reported Outcome Measures) provided to primary care physicians
Number of subjects: 304
Study 31449165 — intervention group
Group type: COMPARATOR
Intervention: Control clinics (standard care without augmented PROMs)
Number of subjects: 304
Study 28347865 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical curettage with adjunct antimicrobial photodynamic therapy (aPDT)
Number of subjects: 48
Study 28347865 — intervention group
Group type: COMPARATOR
Intervention: Mechanical curettage alone
Number of subjects: 48
Study 24841947 — intervention group
Group type: EXPERIMENTAL
Intervention: The Incredible Years Parent‐Toddler Programme (IYPTP)
Number of subjects: 89
Study 24841947 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 89
Study 23458681 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesh reinforcement of stapled left pancreatectomy
Number of subjects: 0
Study 23458681 — intervention group
Group type: COMPARATOR
Intervention: No mesh reinforcement of stapled left pancreatectomy
Number of subjects: 0
Study 20848527 — intervention group
Group type: EXPERIMENTAL
Intervention: Boswelan (3×2 capsules/day; 400 mg each)
Number of subjects: 108
Study 20848527 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 20848527 — intervention group
Group type: EXPERIMENTAL
Intervention: Boswelan
Number of subjects: 108
Study 19918682 — intervention group
Group type: EXPERIMENTAL
Intervention: Healer cream applied 3 times daily
Number of subjects: 60
Study 19918682 — intervention group
Group type: COMPARATOR
Intervention: Nitroglycerine 0.25% cream applied 3 times daily
Number of subjects: 60
Study 19918682 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine 2% cream applied 3 times daily
Number of subjects: 60
Study 17096821 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based obesity prevention programs
Number of subjects: 0
Study 12719046 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (1 mg/kg)
Number of subjects: 34
Study 12719046 — intervention group
Group type: COMPARATOR
Intervention: Etomidate (0.2 mg/kg)
Number of subjects: 34
Study 10911589 — intervention group
Group type: EXPERIMENTAL
Intervention: Home health nursing intervention
Number of subjects: 0
Study 10911589 — intervention group
Group type: COMPARATOR
Intervention: Control group (no home health nursing services)
Number of subjects: 0
Study 9580234 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet + 750 mg UDA + fiber placebo
Number of subjects: 0
Study 9580234 — intervention group
Group type: COMPARATOR
Intervention: Diet + 15 g Pp + UDA placebo
Number of subjects: 0
Study 8503064 — intervention group
Group type: EXPERIMENTAL
Intervention: AIDS educational programs
Number of subjects: 301
Study 3759281 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine, 2 g twice daily for 15 days
Number of subjects: 12
Study 3759281 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31278329 — intervention group
Group type: EXPERIMENTAL
Intervention: Sanghuang-Danshen (SD) phytochemicals
Number of subjects: 17
Study 29902995 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialist Depression Service (SDS)
Number of subjects: 21
Study 29902995 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 21
Study 26798960 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messaging‐based smoking cessation intervention
Number of subjects: 187
Study 26798960 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 187
Study 24288121 — intervention group
Group type: EXPERIMENTAL
Intervention: Topotecan (0.75 mg/m²) on days 1, 2, and 3, etoposide (70 mg/m²) and cisplatin (20 mg/m²) on days 8, 9, and 10 (Arm A)
Number of subjects: 140
Study 24288121 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan (50 mg/m²) and cisplatin (20 mg/m²) on days 1 and 8 followed by etoposide (85 mg/m² PO bid) on days 3 and 10 (Arm B)
Number of subjects: 140
Study 22044970 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium spiral tacks (STs)
Number of subjects: 80
Study 22044970 — intervention group
Group type: COMPARATOR
Intervention: Tissue adhesive (TA)
Number of subjects: 80
Study 22044970 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study 19671086 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (0.08 mg/kg)
Number of subjects: 212
Study 19671086 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentazocine (0.5 mg/kg)
Number of subjects: 212
Study 19095597 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 25 mg once daily for 4 weeks
Number of subjects: 24
Study 19095597 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone in microalbuminuria group
Number of subjects: 24
Study 19095597 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone in macroalbuminuria group
Number of subjects: 24
Study 19095597 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 24
Study 15751766 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized multicomponent intervention (nurse-led, motivational interviewing, 3 months, 4 encounters)
Number of subjects: 151
Study 15751766 — intervention group
Group type: COMPARATOR
Intervention: Usual medical follow-up
Number of subjects: 151
Study 12486433 — intervention group
Group type: EXPERIMENTAL
Intervention: Inoue balloon technique (IBMC)
Number of subjects: 100
Study 12486433 — intervention group
Group type: COMPARATOR
Intervention: Metallic commissurotomy (PMMC)
Number of subjects: 100
Study 9797112 — intervention group
Group type: COMPARATOR
Intervention: Control medium
Number of subjects: 25
Study 9797112 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal lecithin (1 mg/mL for 2 hours)
Number of subjects: 25
Study 8635827 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferiprone (DFP) given to 20 patients (10 beta thalassemia, 10 hemoglobin E-beta thalassemia)
Number of subjects: 41
Study 8635827 — intervention group
Group type: COMPARATOR
Intervention: Control group (21 patients)
Number of subjects: 41
Study 2569381 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone 4 x 1 g i.m. every 2 days
Number of subjects: 28
Study 2569381 — intervention group
Group type: COMPARATOR
Intervention: Penicillin G 1 million IU i.m. daily for 15 days
Number of subjects: 28
Study 773078 — intervention group
Group type: EXPERIMENTAL
Intervention: Piracetam
Number of subjects: 27
Study 773078 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 27
Study 31237981 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese ear acupuncture
Number of subjects: 111
Study 31237981 — intervention group
Group type: EXPERIMENTAL
Intervention: French ear acupuncture
Number of subjects: 111
Study 31237981 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 111
Study 28854534 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 4 mg i.v. after induction of anaesthesia
Number of subjects: 32
Study 28854534 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control group)
Number of subjects: 32
Study 26267418 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressants (ADs) plus mood stabilizers continued for up to 3 years after achieving euthymia for 2 months
Number of subjects: 70
Study 26267418 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressants (ADs) continued
Number of subjects: 70
Study 26267418 — intervention group
Group type: COMPARATOR
Intervention: Antidepressants (ADs) discontinued
Number of subjects: 70
Study 23792189 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Education plus Manual Therapy (PE + MT)
Number of subjects: 118
Study 23792189 — intervention group
Group type: COMPARATOR
Intervention: Patient Education (PE)
Number of subjects: 118
Study 23792189 — intervention group
Group type: COMPARATOR
Intervention: Minimal Control Intervention (MCI)
Number of subjects: 118
Study 22089463 — intervention group
Group type: EXPERIMENTAL
Intervention: IV golimumab 2‐4 mg/kg (± MTX) every 12 weeks
Number of subjects: 643
Study 22089463 — intervention group
Group type: EXPERIMENTAL
Intervention: golimumab 50 mg SC (± MTX) every 4 weeks
Number of subjects: 643
Study 22089463 — intervention group
Group type: COMPARATOR
Intervention: IV placebo + MTX
Number of subjects: 643
Study 22089463 — intervention group
Group type: EXPERIMENTAL
Intervention: golimumab (IV) + MTX
Number of subjects: 643
Study 22089463 — intervention group
Group type: EXPERIMENTAL
Intervention: SC golimumab (LTE)
Number of subjects: 643
Study 22089463 — intervention group
Group type: EXPERIMENTAL
Intervention: IV golimumab (2‐4 mg/kg)
Number of subjects: 643
Study 19097679 — intervention group
Group type: EXPERIMENTAL
Intervention: Light cola drink (group light)
Number of subjects: 8
Study 19097679 — intervention group
Group type: COMPARATOR
Intervention: Regular cola drink (group regular)
Number of subjects: 8
Study 16598368 — intervention group
Group type: EXPERIMENTAL
Intervention: Fracture group
Number of subjects: 125
Study 16598368 — intervention group
Group type: COMPARATOR
Intervention: No fracture group
Number of subjects: 125
Study 14630265 — intervention group
Group type: EXPERIMENTAL
Intervention: (125)I (144 Gy)
Number of subjects: 115
Study 14630265 — intervention group
Group type: COMPARATOR
Intervention: (103)Pd (125 Gy)
Number of subjects: 115
Study 14630265 — intervention group
Group type: EXPERIMENTAL
Intervention: D(90) <100%
Number of subjects: 115
Study 14630265 — intervention group
Group type: COMPARATOR
Intervention: D(90) >=100%
Number of subjects: 115
Study 14630265 — intervention group
Group type: EXPERIMENTAL
Intervention: V(100) <90%
Number of subjects: 115
Study 14630265 — intervention group
Group type: COMPARATOR
Intervention: V(100) >=90%
Number of subjects: 115
Study 16989935 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical assessment by auscultation
Number of subjects: 26
Study 16989935 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical assessment by palpation
Number of subjects: 26
Study 16989935 — intervention group
Group type: COMPARATOR
Intervention: Electrocardiography (ECG)
Number of subjects: 26
Study 10392323 — intervention group
Group type: EXPERIMENTAL
Intervention: Avitriptan (12.7 mg)
Number of subjects: 24
Study 10392323 — intervention group
Group type: EXPERIMENTAL
Intervention: Avitriptan (25.3 mg)
Number of subjects: 24
Study 10392323 — intervention group
Group type: EXPERIMENTAL
Intervention: Avitriptan (38.0 mg)
Number of subjects: 24
Study 9133311 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (0.3 mg/Kg bolus, followed by 0.0028 mg/Kg/min infusion if needed)
Number of subjects: 160
Study 9133311 — intervention group
Group type: COMPARATOR
Intervention: Verapamil (75 micrograms/Kg bolus, with a second dose if needed)
Number of subjects: 160
Study 9133311 — intervention group
Group type: COMPARATOR
Intervention: Sokolow protocol (i.v. digital plus oral quinidine 400 to 1,200 mg)
Number of subjects: 160
Study 9133311 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 160
Study 9133311 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem and Verapamil
Number of subjects: 160
Study 1899392 — intervention group
Group type: EXPERIMENTAL
Intervention: hMG/IUI
Number of subjects: 322
Study 1899392 — intervention group
Group type: COMPARATOR
Intervention: hMG
Number of subjects: 322
Study 1899392 — intervention group
Group type: COMPARATOR
Intervention: IUI
Number of subjects: 322
Study 1899392 — intervention group
Group type: EXPERIMENTAL
Intervention: hMG/IUI (for male factor)
Number of subjects: 322
Study 1899392 — intervention group
Group type: COMPARATOR
Intervention: hMG (for male factor)
Number of subjects: 322
Study 1899392 — intervention group
Group type: COMPARATOR
Intervention: IUI (for male factor)
Number of subjects: 322
Study 1899392 — intervention group
Group type: EXPERIMENTAL
Intervention: hMG/IUI (for cervical factor)
Number of subjects: 322
Study 1899392 — intervention group
Group type: COMPARATOR
Intervention: hMG (for cervical factor)
Number of subjects: 322
Study 1899392 — intervention group
Group type: COMPARATOR
Intervention: IUI (for cervical factor)
Number of subjects: 322
Study 1899392 — intervention group
Group type: EXPERIMENTAL
Intervention: hMG/IUI (for endometriosis)
Number of subjects: 322
Study 1899392 — intervention group
Group type: COMPARATOR
Intervention: hMG (for endometriosis)
Number of subjects: 322
Study 1899392 — intervention group
Group type: EXPERIMENTAL
Intervention: hMG/IUI (for unexplained infertility)
Number of subjects: 322
Study 1899392 — intervention group
Group type: COMPARATOR
Intervention: hMG (for unexplained infertility)
Number of subjects: 322
Study 1899392 — intervention group
Group type: COMPARATOR
Intervention: IUI (for unexplained infertility)
Number of subjects: 322
Study 6344736 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline 400 mg
Number of subjects: 147
Study 6344736 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole 1500 mg
Number of subjects: 147
Study 27430157 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC; 4 × 5-min at 220 mmHg)
Number of subjects: 14
Study 27430157 — intervention group
Group type: COMPARATOR
Intervention: SHAM-RIPC (20 mmHg)
Number of subjects: 14
Study 27430157 — intervention group
Group type: EXPERIMENTAL
Intervention: RIPC
Number of subjects: 14
Study 27430157 — intervention group
Group type: COMPARATOR
Intervention: RIPC and SHAM-RIPC
Number of subjects: 14
Study 26723098 — intervention group
Group type: EXPERIMENTAL
Intervention: Double cord technique with 5% aluminum chloride cords
Number of subjects: 6
Study 26723098 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode laser (810 nm)
Number of subjects: 6
Study 26723098 — intervention group
Group type: COMPARATOR
Intervention: Control (adjacent tooth)
Number of subjects: 6
Study 25158654 — intervention group
Group type: EXPERIMENTAL
Intervention: Fall-prevention DVD program
Number of subjects: 132
Study 25158654 — intervention group
Group type: COMPARATOR
Intervention: Standard fall-prevention education (Control)
Number of subjects: 132
Study 21791146 — intervention group
Group type: EXPERIMENTAL
Intervention: Global DNA methylation measured in leucocytes
Number of subjects: 215
Study 19018865 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplantation (ASCT) with melphalan
Number of subjects: 0
Study 19018865 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction therapy including new drugs
Number of subjects: 0
Study 19018865 — intervention group
Group type: EXPERIMENTAL
Intervention: Consolidation with a second transplant
Number of subjects: 0